Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults

References

• Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine. 2008;26:D35–40. doi:10.1016/j.vaccine.2008.07.065.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pandemic preparedness and response, April 2009 [Internet]. Available at http://www.who.int/influenza/resources/documents/pandemic_guidance_04_2009/en/
   Google Scholar
• Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: A preliminary report of two randomised controlled phase 2 trials. Lancet. 2010;375:41–8. doi:10.1016/S0140-6736(09)62026-2.
   PubMed Web of Science ®Google Scholar
• WHO. Global pandemic influenza action plan to increase vaccine supply. 2006 [ Internet]. Available at http://www.who.int/csr/resources/publications/influenza/WHO_CDS_EPR_GIP_2006_1/en/
   Google Scholar
• Sansyzbay AR, Erofeeva MK, Khairullin BM, Sandybayev NT, Kydyrbayev ZK, Mamadaliyev SM, Kassenov MM, Sergeeva MV, Romanova JR, Krivitskaya VZ, et al. An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/chicken/astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans. Clin Vaccine Immunol. 2013;20:1314–9. doi:10.1128/CVI.00096-13.
   PubMed Web of Science ®Google Scholar
• Tabynov KK, Khairullin BM, Kydyrbayev Zh, Sandybayev NT, Stukova MA, Erofeeva M, Shurygina AP, Kiselev OI, Mamadaliev SM, Sansyzbay AR. Preliminary assessment of safety and immunogenicity of an inactivated whole-virion vaccine against influenza (H1N1) Pdm09 containing aluminum hydroxide adjuvant: A randomized, blinded phase I clinical study. J Vaccines Vaccin. 2013;4:205. doi:10.4172/2157-7560.1000205.
   Google Scholar
• Mamadaliyev SM, Sandybayev NT, Kydyrbayev ZhK, Khairullin BM, Zaitsev VL, Mambetaliyev M, Kassenov MM, Chervyakova OV, Ryskeldinova SZh, Volgin YN, et al. Basic results of development of a production technology and control of a pandemic influenza A/H5N1 vaccine. Influenza Other Respi. Viruses. 5(1):350–353.
   Google Scholar
• Mamadaliyev SM, Sandybayev NT, Kydyrbayev ZhK, Khairullin BM, Zaitsev VL, Mambetaliyev M, Kassenov MM, Chervyakova OV, Ryskeldinova SZh, Volgin YN, et al. Development of production technology and pre-clinical testing of a pandemic influenza A/H1N1 vaccine. Influenza Other Respi. Viruses. 5(1):354–357.
   Google Scholar
• Sarsenbayeva GJ, Khairullin BM, Sansyzbay AR, et al. Comparative study of methods for extraction of highly purified hemagglutinin from H5N1 Influenza virus recombinant strain (A/Astana/6:2/2009). J App Envir Bio Sci. 2013;3:29–35.
   Google Scholar
• Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Nurpeissova A, Sagymbay A, Abitay R, Stukova M, Khairullin B, et al. A novel preservative-free seasonal influenza vaccine safety and immune response studying in the frame of preclinical research. J Med Virol. 2017;89:1168–1173. doi:10.1002/jmv.24771. PMID:28160490.
   PubMed Web of Science ®Google Scholar
• Sarsenbayeva, G, Volgin, Y, Kassenov, M, Issagulov, T, Bogdanov, N, Sansyzbay, A, Abitay, R, Nurpeisova, A, Sagymbay, A, Koshemetov, Z, et al. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: blind, randomized and placebo-controlled trial. J. Med. Virol 2018;90:41–49. https://doi:10.1002/jmv.24922
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar J. Vaccine adjuvants: Current state and future trends. Immunol Cell Biol. 2004;82:488–496. doi:10.1111/j.0818-9641.2004.01272.x.
   PubMed Web of Science ®Google Scholar
• Cerbino-Neto J, Santos AT, Gouvea MI, Pedro RS, Ramos GV, Guaraldo L, Werneck GL. Comparison of adverse events following immunization with pandemic influenza A (H1N1)pdm09 vaccine with or without adjuvant among health professionals in Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz. 2012;107(7):923–927. doi:10.1590/S0074-02762012000700014.
   PubMed Web of Science ®Google Scholar
• Goto N, Kato H, Maeyama J-I, Eto K, Yoshihara S. Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine. 1993;11:914–8. doi:10.1016/0264-410X(93)90377-A.
   PubMed Web of Science ®Google Scholar
• Grohmann G, Francis DP, Sokhey J, Robertson J. Challenges and successes for the grantees and the technical advisory group of WHO's influenza vaccine technology transfer initiative. Vaccine. 2016; 26;34(45):5420–5424. doi:10.1016/j.vaccine.2016.07.047.
   PubMed Web of Science ®Google Scholar
• The Committee for Proprietary Medicinal Products (CHMP). Note for guidance on harmonisation of requirements for influenza vaccines. CPMP /BWP/214/96, 1997 [Internet]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf
   Google Scholar
• Hendriks J, Holleman M, de Boer O, de Jong P, Luytjes W. An international technology platform for influenza vaccines. Vaccine. 2011;29 (1):A8–11. doi:10.1016/j.vaccine.2011.04.124.
   PubMedGoogle Scholar
• Ghendon Y, Markushin S, Vasiliev Y, Akopova I, Koptiaeva I, Krivtsov G, Borisova O, Ahmatova N, Kurbatova E, Mazurina S, et al. Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. J. Med. Virol. 2009;81:494–506. doi:10.1002/jmv.21415.
   PubMed Web of Science ®Google Scholar
• Okamoto S, Matsuoka S, Takenaka N, Haredy AM, Tanimoto T, Gomi Y, Ishikawa T, Akagi T, Akashi M, Okuno Y, et al. Intranasal Immunization with a formalin-inactivated human influenza a virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection. Clin Vaccine Immunol 2012;19(7):979–990. doi:10.1128/CVI.00016-12.
   PubMed Web of Science ®Google Scholar
• Petrovsky N. Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. Drug safety. 2015;38(11):1059–1074. doi:10.1007/s40264-015-0350-4.
   PubMed Web of Science ®Google Scholar
• Morrison-Griffiths S, Gaulton L. Seasonal influenza immunization program outside general practice: An evaluation. Hum Vaccin Immunother. 2016; 12:1:248–251. doi:10.1080/21645515.2015.1099770.
   Google Scholar
• Haugh M, Gresset-Bourgeois V, Macabeo B, Woods A, Samson SI. A trivalent, inactivated influenza vaccine (Vaxigrip®): Summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries. Expert Rev Vaccines. 2017;16(6):545–564. doi:10.1080/14760584.2017.1324302.
   PubMed Web of Science ®Google Scholar
• Sokolova TM, Shuvalov AN, Poloskov VV, Shapoval IM, Kostinov MP. Grippol, Vaxigrip and influvac vaccines–inductors of innate and adaptive immunity factor genes in human blood cells. Zh Mikrobiol Epidemiol Immunobiol. 2014;(5):37–43. PMID:25536769.
   PubMedGoogle Scholar
• Scheifele DW, Ward BJ, Dionne M, Vanderkooi OG, Loeb M, Coleman BL, Li Y, PHAC/CIHR Influenza Research Network (PCIRN). Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial. Vaccine. 2012; 6;30(32):4728–32. doi:10.1016/j.vaccine.2012.05.029.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, Leroux-Roels G. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine. 2008; 2;26(51):6614–9. doi:10.1016/j.vaccine.2008.09.078.
   PubMed Web of Science ®Google Scholar
• Swaan CM, van der Sande MA, Speelman P, Conyn-van Spaendonck MA, Straus SM, Coutinho RA. Adverse events following influenza vaccination: reaction to specific reports and the necessity of a central registration system. Ned Tijdschr Geneeskd. 2007; 29;151(39):2166–9. PMID:17957995.
   PubMedGoogle Scholar